CardioQuip MCH-1000(TM) Earns CE Mark Approval

Advanced temperature control technology to help European hospitals fighting COVID-19 outbreak

COLLEGE STATION, Texas, March 26, 2020 /PRNewswire/ -- CardioQuip(TM), LLC, [] a medical device manufacturer focused on development and commercialization of patient temperature control and cardiovascular perfusion technology announced today it has received CE Mark approval for the MCH-1000(TM) Modular Cooler-Heater Series(TM) []. The MCH-1000 Series of cooler-heaters is now available to European hospital systems fighting the COVID-19 pandemic. [ ]

A cooler-heater device is used to regulate patient temperature in many types of medical procedures, especially those involving the heart and lungs. Most notably, the MCH-1000 can potentially be used to treat acute respiratory distress syndrome (ARDS) associated with COVID-19 through a treatment called Extracorporeal Membrane Oxygenation (ECMO)(1). ECMO provides increased systemic oxygen delivery and mitigates ventilator-induced lung injury.

"Landing the CE Mark is a tremendous milestone for CardioQuip," said Doug Platt, CEO. "The approval allows us to offer our technology to major hospitals all over the European Union (EU) at a time when it is greatly needed."

The CE Mark confirms that the MCH-1000 meets the Essential Requirements of the Medical Device Directive (93/42/EEC). CardioQuip also received ISO 134385:2016 certification of its quality management system following completion of an audit by BSI, an EU Notified Body. The MCH-1000 received FDA 510(k) clearance in the United States in 2011.

Numerous patient deaths linked to non-tuberculosis mycobacterium (NTM) growth in European manufactured cooler-heaters have highlighted the need for safety and water quality in cooler-heaters. The safety of the MCH-1000's open tank design paired with its simplified cleaning protocol and ease of use have made it the best-selling cooler-heater in the U.S. Market.

"We are excited to be in the final stages of agreements with European distribution partners to aide our commercialization efforts and get the MCH-1000 to the EU as quickly as possible," added Platt.

For more information on the MCH-1000(TM) and CardioQuip, follow us on Twitter @CardioQuip [] and LinkedIn [] or visit [].

(1)MacLaren G, Fisher D, Brodie D. Preparing for the Most Critically Ill Patients With COVID-19: The Potential Role of Extracorporeal Membrane Oxygenation. JAMA. Published online February 19, 2020. doi:10.1001/jama.2020.2342

Logo - []

CONTACT: Will Otto, 713-818-0947,

Web site:

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234